StockNews.com Upgrades uniQure (NASDAQ:QURE) to “Sell”

uniQure (NASDAQ:QURE) was upgraded by research analysts at StockNews.com to a “sell” rating in a research note issued to investors on Wednesday.

Other research analysts have also recently issued research reports about the stock. The Goldman Sachs Group lowered their price target on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. Royal Bank of Canada dropped their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $20.00 to $52.00 in a report on Tuesday. Cantor Fitzgerald raised their target price on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of uniQure in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $27.33.

uniQure Stock Up 109.6 %

Shares of NASDAQ QURE opened at $15.30 on Wednesday. The stock has a market cap of $745.72 million, a PE ratio of -3.08 and a beta of 0.89. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12-month low of $3.73 and a 12-month high of $17.39. The company has a 50-day moving average of $6.42 and a 200 day moving average of $6.15.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, sell-side analysts predict that uniQure will post -3.74 EPS for the current fiscal year.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after acquiring an additional 109,740 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of uniQure in the 2nd quarter valued at $79,000. Clear Harbor Asset Management LLC lifted its position in shares of uniQure by 35.2% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 12,500 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of uniQure during the 2nd quarter worth $815,000. Finally, Privium Fund Management B.V. raised its stake in uniQure by 10.6% in the second quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company’s stock valued at $2,869,000 after buying an additional 61,501 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.